Immunoassay technology developer Spear Bio Unveils its NAB-SureTM SARS-CoV2 Neutralizing Antibody Test Kit at the American Association for Clinical Chemistry Annual Event

Spear Bio recognized by AACC as “Best Abstract in Metabolomics” Poster

WOBURN, Massachusetts., September 2, 2022 /PRNewswire/ — The developer of an ultrasensitive protein detection platform, Spear Bio (www.spear.bio), presented its innovative immunoassay technology at the recent American Association for Clinical Chemistry scientific meeting and clinical laboratory expo, celebrated in chicago.

At the AACC event, Spear Bio introduced its first product to market: the NAB-Sure™ SARS-CoV-2 Neutralizing Antibody (NAb) Test Kit. Based on proprietary SPEAR technology, the NAB-Sure™ SARS-CoV-2 assay is a powerful research tool in the fight against the coronavirus disease COVID-19. It serves a variety of applications, including COVID-19 serological surveillance, vaccine efficacy testing, and longitudinal antibody durability testing.

Ultrasensitive protein detection from small samples

The immunoassay test kit is capable of detecting ultrasensitive proteins for small sample sizes, such as dried blood spot (DBS) samples from a finger prick, which can be collected at home. The assay is in high agreement with the precision of plaque reduction neutralization testing (PRNT), without the safety concerns and lengthy workflows of a cell-based assay. The NAB-Sure™ SARS-CoV-2 Assay provides a critical boost for COVID-19 vaccine developers, clinical laboratories, and healthcare researchers.

SPEAR technology enhances testing of SARS-CoV-2 NAbs with support for ultrasensitive automated test compatibility for many sample types, including DBS, plasma, and serum, and excellent lab-to-lab consistency in measurement results, even when comparing different types of samples.

Award for Best Abstract in Metabolomics

Co-founder and CTO of Spear Bio, feng xuanY yu wangPh.D., Head of Application Development, were recognized as the winners of the 2022 AACC Division Award for Best Abstract in Metabolomics for their Technical Poster B-087: “A New SARS CoV Neutralizing Antibody Titer Measurement Assay.” 2, ultrasensitive, high throughput, and quantitative on dried blood spot samples.”

See also  Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

The poster session provided information on how Spear Bio’s proprietary SPEAR technology provides real-time polymerase chain reaction (PCR) qualitative and quantitative NAb titer measurements. The poster explored how a two-step polymerase extension can generate a PCR-detectable signal with little background noise. It is this high signal-to-noise ratio that allows for higher detection sensitivity compared to standard ELISA test methods. The poster further explored the ability of the SPEAR platform to test neutralizing antibodies for new variants of SARS-CoV-2. (Link to abstract here https://www.abstractsonline.com/pp8/#!/10594/presentation/617)

Spear Bio’s validated SPEAR technology provides a secure path to COVID-19 healthcare solutions for researchers facing tight restrictions and limited sample sizes, such as government agencies or research companies working with microsample collection devices such as DBS.

About Spear Biography

Launch Biography (www.spear.bio), founded in 2021 by harvard researchers at the Wyss Institute, is based in Woburn, MA. The company is dedicated to the next generation of ultrasensitive immunoassay technology and collaborates closely with academic researchers, clinicians, and industry to develop more ultrasensitive screening approaches in support of clinical research, noninvasive sample collection methods, and laboratory diagnostics of Vanguard.

Visit www.spear.bio to learn more about our innovative approach to protein detection. Fill out the contact form to learn more and how to partner with Spear Bio on future innovations.

About the AACC

The American Association for Clinical Chemistry, based in Washington D.C., is a worldwide scientific and medical professional organization dedicated to clinical laboratory science and its applications to health care. The association’s annual scientific meeting and clinical laboratory expo is an opportunity to learn about cutting-edge technology and connect with world leaders in clinical chemistry, molecular diagnostics and other areas of laboratory medicine. (www.aacc.org)

See also  The growing insider risk of emerging health technology

SOURCE Spear Bio

Leave a Comment